Alkem Laboratories Limited has informed the Exchange regarding a press release dated September 22, 2025, titled "Alkem launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer.".
Alkem Laboratories Limited has informed the Exchange regarding a press release dated September 22, 2025, titled "Alkem launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer.".